Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas
NCT03356782
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Sarcoma
Osteoid Sarcoma
Ewing Sarcoma
Interventions
BIOLOGICAL:
Sarcoma-specific CAR-T cells
Sponsor
Shenzhen Geno-Immune Medical Institute